Why biotech can’t be treated like tech, and why many investors get this wrong

One of the most common and costly mistakes in biotechnology investment is treating the sector like technology. Too often, biotech is evaluated through the same lens as software or digital platforms — fast cycles, rapid pivots and early exits. This misunderstanding has distorted investment decisions, misaligned capital expectations and slowed the development of sustainable biotech ecosystems, particularly in emerging markets.

Biotechnology is structurally different. It does not scale through code alone, nor does it reward speed for its own sake. Biotech scales through science, regulation, manufacturing and long-term validation. These elements are not inefficiencies; they are safeguards. Treating them as friction misunderstands both the purpose and the economics of the sector.

Technology businesses are designed to iterate quickly and fail cheaply. Biotech businesses are designed to fail early, learn rigorously and succeed deliberately. Clinical timelines cannot be compressed without compromising safety. Regulatory processes are not optional hurdles but essential gates of legitimacy. Manufacturing is not an afterthought but a core driver of value creation. When investors apply tech-style expectations to biotech, they often push companies toward premature commercialization, underfund critical development stages, or abandon viable science before it matures. 

Biotech is not slow technology. It is a different asset class entirely.

This misalignment creates three recurring problems. First, capital becomes impatient, demanding traction before scientific proof is complete. Second, founders are incentivized to overpromise timelines and underplay risk. Third, ecosystems develop fragility rather than resilience, as companies are built to impress investors rather than survive regulatory reality.

Good biotech investing requires a fundamentally different mindset. Value is not created through user growth curves or rapid market capture. It is built incrementally through proof points: robust preclinical data, well-designed clinical trials, regulatory progress, scalable manufacturing and credible market access strategies. Each milestone de-risks the asset, but only if capital is aligned with the process.

In markets like Saudi Arabia, this distinction is especially important. The Kingdom’s investment in biotechnology is not driven by short-term speculation but by long-term national priorities — health security, advanced manufacturing and economic diversification. These objectives require investors who understand that biotech value compounds over time and that patience is not a weakness, but a strategic advantage.

Global biotech hubs did not emerge because investors waited for certainty. They emerged because capital understood the rules of the game early. In Boston, Basel and Singapore, investors learned to price risk appropriately, support companies through long development cycles, and reward disciplined execution. Where capital aligned with science, ecosystems flourished. Where it did not, progress stalled.

Another misconception is that biotech underperforms because it is slow. In reality, biotech underperforms when expectations are mismanaged. When timelines are understood, risks priced correctly and governance structures aligned, biotech can deliver durable returns with defensible moats. Intellectual property, regulatory exclusivity, and complex manufacturing create barriers that most technology businesses can only aspire to.

For investors entering biotech today, the lesson is clear: This is not a sector for those seeking quick wins, it is a sector for those willing to build. It rewards investors who combine scientific literacy with capital discipline, and who recognize that execution matters more than speed.

Saudi Arabia has a rare opportunity to get this right from the start. By attracting capital that understands biotech on its own terms, the Kingdom can avoid the mistakes that have slowed other emerging markets. Treating biotech as tech may feel familiar, but familiarity is not a strategy.

Biotech is not slow technology. It is a different asset class entirely. Investors who accept this reality will help shape the next generation of healthcare and manufacturing. Those who do not will continue to ask why promising science fails to scale.

• Dr. Huda Alfardus is a businesswoman and biotech investment expert focused on innovation, venture capital and expanding women’s participation in business and investment markets.